⚡ Flash Summary
LIVEN Pharma Limited is issuing right shares to existing shareholders at a ratio of 21.496 right shares for every 100 shares held. The right shares are offered at par value of PKR 10 per share. Shareholders must accept and pay for the right shares by December 22, 2025. This issuance aims to raise capital, providing shareholders the opportunity to increase their stake in the company.
📌 Key Takeaways
- 📢 LIVEN Pharma is issuing right shares at a ratio of 21.496% for every 100 shares held.
- 💰 The issue price is PKR 10/- per share, which is the par value.
- 🗓️ The offer is available from December 1, 2025, to December 15, 2025, for trading of rights.
- ⏳ Shareholders must accept and pay for the shares on or before December 22, 2025.
- 🏦 Payment can be made through Meezan Bank Limited at all branches.
- 💻 Online payment option is available through 1Link for IAS account holders.
- 🧾 Physical shareholders can renounce rights by depositing them into a CDS account.
- 🔄 Shareholders must request their CDC participant to initiate the right subscription request.
- 🚫 Fractional right entitlements will be consolidated and disposed of on the Securities Exchange.
- 🏦 Payment can be made via cash, cheque, demand draft, or pay order.
- ⏳ Securities against paid Right Subscription Request will be credited within 14 business days from the last payment date (December 22, 2025).
- 📄 Detailed procedures for exercising rights in CDS are provided.
- 🌐 The International Bank Account Number (IBAN) is PK58MEZN0098860113180818.
- ✅ Right subscription request can be initiated for full or partial right offer.
🎯 Investment Thesis
I recommend a HOLD position. While the right issue presents an opportunity for existing shareholders to increase their stake at par value, the potential dilution effect and the uncertainty of how efficiently the capital will be used warrant a cautious approach. Further analysis is required to evaluate the company’s growth prospects and profitability improvements. A reassessment is needed post the capital raise and deployment.
Disclaimer: AI-generated analysis. Not financial advice.